Welcome to our dedicated page for Inmune Bio news (Ticker: INMB), a resource for investors and traders seeking the latest updates and insights on Inmune Bio stock.
INmune Bio Inc. develops clinical-stage immunology and biotechnology treatments designed to target the innate immune system in disease. Company news commonly centers on three platforms: CORDStrom, a pooled allogeneic human umbilical cord-derived mesenchymal stromal/stem cell platform; XPro, a dominant-negative TNF platform intended to selectively neutralize soluble TNF; and INKmune, a cell-based medicine designed to prime natural killer cells against residual cancer.
Recurring updates include clinical and preclinical data, regulatory pathway discussions, manufacturing and collaboration agreements, conference presentations, shareholder communications, and quarterly or annual financial results. Coverage also reflects program areas such as recessive dystrophic epidermolysis bullosa, early Alzheimer’s disease, neuroinflammation, inflammatory disease and oncology.
INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage biotechnology firm, will host a conference call on May 14, 2020, at 4:30 PM ET to discuss its first-quarter financial results ending March 31, 2020. The company focuses on developing treatments leveraging the innate immune system, with ongoing clinical trials for various platforms including DN-TNF for diseases such as COVID-19 and cancer, and Natural Killer Cell Priming with INKmune™. These treatments are aimed at chronic inflammation and hematologic malignancies.
INmune Bio, a clinical-stage immunology company, announced participation by CEO RJ Tesi in a COVID-19 therapeutics panel at Maxim Group’s Infectious Disease Virtual Conference on May 5, 2020. Tesi will discuss treating COVID-19's inflammatory aspects, attributing significant roles to hypertension and obesity, which increase hospitalization risks. He emphasized endothelial activation by soluble TNF as a critical factor in severe COVID-19 cases, advocating for sTNF-targeted therapies that mitigate inflammation without immunosuppression. INmune Bio's product platforms focus on therapies addressing innate immune dysfunction in diseases including cancer, Alzheimer's, and NASH, utilizing cutting-edge approaches to treatment.